Oct 17, 2022 05:26 PM (GMT+8) · EqualOcean
Chuangmo Biotechnology (Chinese: 创模生物), CRO service provider for oncology and tumor immunopharmacology evaluation, completed a new round of financing worth tens of millions of CNY recently. The round was led by Zhongguancun Co-Innovative Fund (Chinese: 中关村协同创新基金), with the participation from ZBJL Capital (Chinese: 中博聚力). The funds will be used to support the construction of new laboratory facilities, and the development and construction of new pre-clinical research platforms. Founded in 2020, Chuangmo Biotechnology has established a comprehensive pre-clinical service platform, and the company is now in a period of high growth.